ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENINGOCOCCAL-C CONJUGATED VACCINE IN THE SECOND YEAR OF LIFE

We report on the results of the 12-month follow-up of children aged 14 to 18 months who received primary and booster vaccinations with either a meningococcal-C vaccine conjugated to tetanus toxoid or CRM(197). Seroprotection (92.8%) and geometric mean titers/serum bactericidal activity (410.5; 95% C...

Descripción completa

Detalles Bibliográficos
Autores: Diez-Domingo J, Planelles-Cantarino MV, Baldo-Torrenti JM, Ubeda-Sansano I, Jubert-Rosich A, Puig-Barbera J, Gutierrez-Gimeno MV
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2010
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p3424
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/3424
Access Level:acceso abierto
Palabra clave:Neisseria meningitidis
serotype C
immunization
secondary
meningococcal vaccines
Descripción
Sumario:We report on the results of the 12-month follow-up of children aged 14 to 18 months who received primary and booster vaccinations with either a meningococcal-C vaccine conjugated to tetanus toxoid or CRM(197). Seroprotection (92.8%) and geometric mean titers/serum bactericidal activity (410.5; 95% CI: 273.4-616.3) were higher in children receiving the meningococcal serogroup C tetanus toxoid conjugate, compared with 61.5% and serum bactericidal antibody geometric mean titer of 45.1 (95% CI: 28.5-71.3) when MenC-CRM(197) conjugate was used.

Similares en LA Referencia